One family’s story of a life-extending medicine for pancreatic cancer — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Daraxonrasib showed a 45% reduction in tumor size for Bobby Senaha, eliminated lung metastases, and allowed him to stop pain medication within weeks of starting treatment.
- Bobby Senaha remained on daraxonrasib for 29 weeks, gaining 10 months of improved quality time with his family before his cancer mutated and progressed.
- Clinical trial participation required frequent travel from Hawaii to San Antonio, involving flights, scans, and clinic visits every 21 days, straining even a well-resourced family.
- Dana Senaha emphasized that despite having strong insurance, flexible jobs, and family support, the logistical burden of accessing daraxonrasib was overwhelming.
- FDA approval of daraxonrasib follows early trial data Bobby helped generate, with another patient, Peter, now accessing the drug through expanded access at a local pharmacy.
- Access to daraxonrasib remains a critical challenge for patients without financial stability, geographic proximity to specialists, or ability to navigate complex healthcare systems.
Why it matters: Even with FDA approval, daraxonrasib’s real-world impact is limited by cost, geography, and system complexity—patients without Bobby Senaha’s advantages may gain little from the breakthrough. The 10 extra months he had are not guaranteed for others, making access a determinant of survival.
Ask SkimNews
